These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33358743)

  • 1. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
    Kandeel EZ; Madney Y; Eldin DN; Shafik NF
    Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tracing Leukemia Stem Cells and Their Influence on Clinical Course of Adult Acute Myeloid Leukemia.
    Kandeel EZ; El Sharkawy N; Hanafi M; Samra M; Kamel A
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):383-393. PubMed ID: 32201129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Real-world Perspective of CD123 Expression in Acute Leukemia as Promising Biomarker to Predict Treatment Outcome in B-ALL and AML.
    Das N; Gupta R; Gupta SK; Bakhshi S; Malhotra A; Rai S; Singh S; Prajapati VK; Sahoo RK; Gogia A; Sharma A; Kumar L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e673-e684. PubMed ID: 32561191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.
    Chávez-González A; Dorantes-Acosta E; Moreno-Lorenzana D; Alvarado-Moreno A; Arriaga-Pizano L; Mayani H
    Arch Med Res; 2014 May; 45(4):343-50. PubMed ID: 24751333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia.
    Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L
    Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-3 receptor α chain (CD123) is preferentially expressed in immature T-ALL and may not associate with outcomes of chemotherapy.
    Du W; Li J; Liu W; He Y; Yao J; Liu Y; Lin J; Zheng J
    Tumour Biol; 2016 Mar; 37(3):3817-21. PubMed ID: 26474588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression and Clinical Significance of Leukemia Stem Cell Antigen in Acute Myeloid Leukemia].
    Yao DD; Han BQ; Han YF; Zhang YQ; Jin YL; Dai HB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1583-1588. PubMed ID: 30501688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
    Almohsen F; Al-Mudallal SS
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia.
    Roug AS; Larsen HØ; Nederby L; Just T; Brown G; Nyvold CG; Ommen HB; Hokland P
    Br J Haematol; 2014 Jan; 164(2):212-22. PubMed ID: 24152218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
    Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
    Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
    [No Abstract]   [Full Text] [Related]  

  • 13. Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Yanagisawa B; Perkins B; Karantanos T; Levis M; Ghiaur G; Smith BD; Jones RJ
    Leuk Res; 2020 Dec; 99():106477. PubMed ID: 33220589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes of Leukemia Stem Cells in Acute Myeloid Leukemia before and after Treatment].
    Lv JT; Yang ZG; Guang YH; Lin ZS; Xiao XX; Liu D; Shi M; Wang WS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):658-664. PubMed ID: 29950200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center.
    Tiribelli M; Michelutti A; Cavallin M; Di Giusto S; Fanin R; Damiani D
    Turk J Haematol; 2021 Jun; 38(2):119-125. PubMed ID: 33596632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.
    Adnan Awad S; Kamel MM; Ayoub MA; Kamel AM; Elnoshokaty EH; El Hifnawi N
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S19-S24.e1. PubMed ID: 27521317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Universal monitoring of minimal residual disease in acute myeloid leukemia.
    Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
    JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunophenotyping of leukemic stem cells and chromosome karyotype characteristics in Uyghur leukemia pediatric patients].
    Hailiqiguli N; Yan M
    Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):501-4. PubMed ID: 24257300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
    Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
    Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of CD200 and CD56 Expression in Patients with Acute Myeloid Leukemia.
    Aref S; Abousamra N; El-Helaly E; Mabed M
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):743-748. PubMed ID: 32212802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.